Chronic hepatitis B
Conditions
Interventions
Group 1:Tenofovir alafenamide, HBV vaccine, HBIG
Group 2:Tenofovir alafenamide, HBV vaccine, HBIG
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
20 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Pregnant women; (2) HBsAg and HBeAg positivity for more than 6 months; (3) HBV DNA positive.
Exclusion criteria
Exclusion criteria: (1) With comorbidity of cirrhosis and/or hepatocellular carcinoma; (2) Coinfection with human immunodeficiency virus (HIV) or other hepatotropic virus (such as hepatitis C virus, et al); (3) With comorbidity of alcoholic liver diseases, fatty liver diseses, autoimmune liver hepatitis, drug-induced liver injury and genetic liver diseases; (4) With comorbidity of systemic disorders of the mothers (such as hypertension and diabetes, et al) or fetus; (5) A history of abortion, pregnancy loss, or congenital malformation in a previous pregnancy; (6) With comorbidity of psychiatric disorders and psychological disorders; (7) Severe abnormality of peripheral blood cell counts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of mother-to-child transmission;Birth defect; | — |
Secondary
| Measure | Time frame |
|---|---|
| The percentage of mothers who had an HBV DNA level of less than 200,000 IU per milliliter at delivery;Maternal HBeAg-seroconverion rate;Maternal ALT elevation or normalization rate;Maternal renal function;Maternal bone marker;Newborn's Apgar score;Newborn's growth parameters; | — |
Countries
China
Contacts
Public ContactQing-Lei Zeng, Zu-Jiang Yu
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed